This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use
by Zacks Equity Research
Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Bristol Myers (BMY) sBLA for Reblozyl Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) sBLA seeking label expansion of Reblozyl for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia gets priority review by the FDA.
Aurinia (AUPH) Stock Up on Potential Acquisition Rumors
by Zacks Equity Research
Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.
Pharma Stock Roundup: FDA Panel Vote for MRK COVID Pill, JNJ Omicron Jab Plan
by Kinjel Shah
FDA panel votes for Merck's (MRK) COVID-19 antiviral pill. AbbVie (ABBV) seeks approval for Skyrizi for Crohn's disease in Europe
Merck (MRK) Vaxneuvance sBLA for Pediatrics Gets Priority Review
by Zacks Equity Research
Merck (MRK) is seeking label expansion for Vaxneuvance for use in pediatric patients aged six weeks through 17 years for the prevention of invasive pneumococcal disease. A decision is expected by on Apr 1, 2022.
AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.
Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote
by Zacks Equity Research
An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.
Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study
by Zacks Equity Research
The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.
Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas
by Zacks Equity Research
Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.
Stock Market News for Nov 30, 2021
by Zacks Equity Research
Benchmarks closed higher on Monday after President Joe Biden reassured Americans that despite the latest Omicron coronavirus variant scare, the country will not undergo shutdowns or lockdowns.
Bristol Myers (BMY) Top Drugs Maintain Momentum Amid Competition
by Zacks Equity Research
Bristol Myers' (BMY) performance has been good of late, driven by Revlimid, Eliquis, Opdivo and its new product portfolio amid stiff competition.
Merck (MRK) COVID Pill Less Effective in Final Study, Stock Down
by Zacks Equity Research
Merck's (MRK) new data from a phase III study shows its COVID-19 antiviral pill is less effective than previously reported.
Pharma Stock Roundup: FDA Nod to COVID Jab for All Adults, CHMP Nod to Shot for Kids
by Kinjel Shah
FDA authorizes booster doses of COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna for all adults. CHMP gives nod to Pfizer/BioNTech's vaccine for young kids.
Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy
by Zacks Equity Research
The European Commission grants marketing authorization to Gilead's (GILD) Trodelvy as a monotherapy for the second-line treatment of adults with metastatic triple-negative breast cancer.
Bristol Myers (BMY) Zeposia Gets EC Nod for Ulcerative Colitis
by Zacks Equity Research
Bristol Myers (BMY) wins EC approval for Zeposia for a second indication ??? ulcerative colitis.
Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC
by Zacks Equity Research
Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.
Gilead (GILD) Files BLA for Bulevirtide for Hepatitis Delta Virus
by Zacks Equity Research
Gilead (GILD) submits a biologics license application to the FDA for bulevirtide for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.
Bristol Myers' (BMY) Cardiovascular Drug Review Extended by FDA
by Zacks Equity Research
Bristol Myers (BMY) announces extension of FDA review of its cardiovascular drug mavacamten. The new target action date is Apr 28, 2022.
Merck's (MRK) Keytruda Gets Approval for Certain RCC Patients
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Gilead (GILD) Exercises Options to Three Arcus Programs
by Zacks Equity Research
Gilead (GILD) exercises options to Arcus' anti-TIGIT Program (domvanalimab and AB308), etrumadenant (A2a/A2b Adenosine Receptor Antagonist), and quemliclustat (small Molecule CD73 Inhibitor).
Mirati (MRTX) to Begin Clinical Study in MTAP-Deleted Cancers
by Zacks Equity Research
Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.
Goldman Fans Can Reap Returns From S&P 500 ETFs in 2022
by Sanghamitra Saha
Goldman Sachs (GS) this week said that it expects the S&P 500 to rise 9% to 5,100 by the end of 2022, as quoted on a Yahoo Finance article.
Atea (AVIR) Plunges on Termination of Collaboration With Roche
by Zacks Equity Research
Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.